Price target
19.620.000.00%
The 24 analysts offering 1 year price forecasts for AB3A have a max estimate of — and a min estimate of —.
Analyst rating
Based on 27 analysts giving stock ratings to AB3A in the past 3 months.
EPS
Reported
Estimate
Reported
Estimate
Surprise
Revenue
Reported
Estimate
Reported
Estimate
Surprise
This info isn't a recommendation for what you should personally do, so please don't take the data as investment advice. As with any trade, always look first, then leap. Read more in the Terms of Use.
Frequently Asked Questions
AB3A EPS for the last quarter is 1.60 EUR despite the estimation of 0.71 EUR. In the next quarter EPS is expected to reach −0.58 EUR. Track more of Sarepta Therapeutics, Inc. financials and stay on top of what is up with the company.
In the next quarter Sarepta Therapeutics, Inc. revenue is expected to reach 285.38 M EUR. Check out Sarepta Therapeutics, Inc. revenue and earnings and make informed decisions.
According to analysts, AB3A price target is 19.62 EUR with a max estimate of 68.37 EUR and a min estimate of 4.27 EUR. Check if this forecast comes true in a year, meanwhile watch Sarepta Therapeutics, Inc. stock price chart and keep track of the current situation with AB3A news and stock market news.
We've gathered opinions of 27 analysts rating AB3A stock in the past 3 months. Most of them backed up the neutral trend, and after taking into account other opinions, the overall rating was calculated as neutral. Note that it's not a trading advice — your own analysis is still required.